Corvus Pharmaceuticals, Inc.
CRVS
$6.94
-$0.31-4.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.08% | 13.36% | 30.74% | 27.46% | 10.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.87% | 58.68% | 43.99% | 30.49% | 5.57% |
| Operating Income | -72.87% | -58.68% | -43.99% | -30.49% | -5.57% |
| Income Before Tax | -87.66% | 366.50% | -82.07% | -570.28% | 34.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.66% | 366.50% | -82.07% | -570.28% | 34.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.66% | 366.50% | -82.07% | -570.28% | 34.46% |
| EBIT | -72.87% | -58.68% | -43.99% | -30.49% | -5.57% |
| EBITDA | -73.00% | -58.91% | -44.35% | -30.81% | -5.87% |
| EPS Basic | -43.98% | 281.08% | -30.58% | -392.16% | 47.85% |
| Normalized Basic EPS | -44.17% | 281.16% | -30.66% | -391.91% | 47.90% |
| EPS Diluted | -43.98% | -10.17% | -30.58% | -392.16% | 47.85% |
| Normalized Diluted EPS | -44.17% | 273.87% | -30.66% | -391.91% | 47.90% |
| Average Basic Shares Outstanding | 30.25% | 47.08% | 39.37% | 36.20% | 25.71% |
| Average Diluted Shares Outstanding | 30.25% | 53.25% | 39.37% | 36.20% | 25.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |